Inhibition of SUR1 decreases the vascular permeability of cerebral metastases

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 535-543

  Thompson, Eric M ^a   Pishko, Gregory L ^a   Muldoon, Leslie L ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GADODIAMIDE; GLIBENCLAMIDE; GLUCOSE; PROTEIN ZO1; SULFONYLUREA RECEPTOR 1; ABCC8 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIMETABOLITE; SULFONYLUREA RECEPTOR; TJP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; BRAIN METASTASIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOIMMUNOPRECIPITATION; RAT; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; MELANOMA; METABOLISM; NUDE RAT; SECONDARY; SMALL CELL LUNG CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TIGHT JUNCTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DEXAMETHASONE; GENE EXPRESSION; GLYBURIDE; INFUSIONS, SUBCUTANEOUS; MELANOMA; RATS; RATS, NUDE; SMALL CELL LUNG CARCINOMA; SULFONYLUREA RECEPTORS; TIGHT JUNCTIONS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84877049950     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13164     Document Type: Article

References (46)

1. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, and Jain RK (2011). The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8, 344-356.
2. Dolecek TA, Propp JM, Stroup NE, and Kruchko C (2012). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14, 1-49.
3. Ortuzar W, Hanna N, Pennella E, Peng G, Langer C, Monberg M, and Scagliotti G (2012). Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 13, 24-30.
4. Sharma M and Abraham J (2007). CNS metastasis in primary breast cancer. Expert Rev Anticancer Ther 7, 1561-1566.
5. Gaudino S, Di Lella GM, Russo R, Lo Russo VS, Piludu F, Quaglio FR, Gualano MR, De Waure C, and Colosimo C (2012). Magnetic resonance imaging of solitary brain metastases: main findings of nonmorphological sequences. Radiol Med 117, 1225-1241.
6. Andersen C and Jensen FT (1998). Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir (Wien) 140, 919-924.
7. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, and Batchelor TT (2009). VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 6, 229-236.
8. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards NA, and Oldfield EH (1996). Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 98, 1400-1408.
9. Piette C, Munaut C, Foidart JM, and Deprez M (2006). Treating gliomas with glucocorticoids: from bedside to bench. Acta Neuropathol 112, 651-664.
10. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, and van Putten WL (1994). Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44, 675-680.
11. Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, and Neuwelt EA (2011). Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol 13, 51-60.
12. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, Pike MM, and Neuwelt EA (2009). Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 29, 853-860.
13. Thompson EM, Dosa E, Kraemer DF, and Neuwelt EA (2010). Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 67, 87-93.
14. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25, 4722-4729.
15. Omuro AM and Delattre JY (2008). What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Curr Opin Neurol 21, 717-719.
16. Chen M, Dong Y, and Simard JM (2003). Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci 23, 8568-8577.
17. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, and Gerzanich V (2006). Newly expressed SUR1--regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 12, 433-440.
18. Simard JM, Kilbourne M, Tsymbalyuk O, Tosun C, Caridi J, Ivanova S, Keledjian K, Bochicchio G, and Gerzanich V (2009). Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J Neurotrauma 26, 2257-2267.
19. Simard JM, Geng Z, Woo SK, Ivanova S, Tosun C, Melnichenko L, and Gerzanich V (2009). Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J Cereb Blood Flow Metab 29, 317-330.
20. U.S. Food and Drug Administration (2008). Micronase - glyburide tablet, September 2008 update. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017498s027lbl.pdf.
21. transmeasurements obtained with conventional and first pass pharmacokinetic models in human gliomas. J Magn Reson Imaging 19, 527-536.
22. trans) related to histologic grade in human gliomas? AJNR Am J Neuroradiol 26, 2455-2465.
23. Mills SJ, Soh C, Rose CJ, Cheung S, Zhao S, Parker GJ, and Jackson A (2010). Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging-derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 31, 549-553.
24. Li X, Rooney WD, Varallyay CG, Gahramanov S, Muldoon LL, Goodman JA, Tagge IJ, Selzer AH, Pike MM, Neuwelt EA, et al. (2010). Dynamic-contrastenhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. J Magn Reson 206, 190-199.
25. 1 -weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10, 223-232.
26. Woltjer RL, Nghiem W, Maezawa I, Milatovic D, Vaisar T, Montine KS, and Montine TJ (2005). Role of glutathione in intracellular amyloid-α precursor protein/carboxy-terminal fragment aggregation and associated cytotoxicity. J Neurochem 93, 1047-1056.
27. ATP channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain. FEBS Lett 401, 59-64.
28. Suckow MA, Weisbroth SH, and Franklin CL (2006). The Laboratory Rat. Elsevier Academic Press, Burlington, MA.
29. Schiffer D, Annovazzi L, Caldera V, and Mellai M (2010). On the origin and growth of gliomas. Anticancer Res 30, 1977-1998.
30. Bauer AT, Burgers HF, Rabie T, and Marti HH (2010). Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J Cereb Blood Flow Metab 30, 837-848.
31. Simard JM, Tsymbalyuk O, Ivanov A, Ivanova S, Bhatta S, Geng Z, Woo SK, and Gerzanich V (2007). Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest 117, 2105-2113.
32. Ningaraj NS, Rao MK, and Black KL (2003). Adenosine 5′-triphosphatesensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res 63, 8899-8911.
33. Simard JM, Kahle KT, and Gerzanich V (2010). Molecular mechanisms of microvascular failure in central nervous system injury-synergistic roles of NKCC1 and SUR1/TRPM4. J Neurosurg 113, 622-629.
34. Wang W, Dentler WL, and Borchardt RT (2001). VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 280, H434-H440.
35. - and mediates trans-epithelial resistance in cultured endothelial and epithelial cells. Cell Tissue Res 323, 117-125.
36. Meyer G and Badenhoop K (2003). Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin (Munich) 98, 266-270.
37. Epocrates (2012). Dexamethasone. Available at: https://online.epocrates.com/noFrame/showPage.do?method=drugs&MonographId=189&ActiveSectionId=6.
38. Epocrates (2012). DiaBeta, glyburide. Available at: https://online.epocrates.com/noFrame/showPage.do?method=drugs&MonographId=626.
39. Ferrier MC, Sarin H, Fung SH, Schatlo B, Pluta RM, Gupta SN, Choyke PL, Oldfield EH, Thomasson D, and Butman JA (2007). Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9, 546-555.
40. Chu JP, Mak HK, Yau KK, Zhang L, Tsang J, Chan Q, and Ka-Kit Leung G (2012). Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent diffusion coefficient) parameters in brain tumors at 3 Tesla. Cancer Imaging 12, 1-6.
41. Haris M, Husain N, Singh A, Awasthi R, Singh Rathore RK, Husain M, and Gupta RK (2008). Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas. J Magn Reson Imaging 28, 588-597.
42. Harrer JU, Parker GJ, Haroon HA, Buckley DL, Embelton K, Roberts C, Baleriaux D, and Jackson A (2004). Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging 20, 748-757.
43. Law M, Young R, Babb J, Rad M, Sasaki T, Zagzag D, and Johnson G (2006). Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 27, 1975-1982.
44. Radjenovic A, Dall BJ, Ridgway JP, and Smith MA (2008). Measurement of pharmacokinetic parameters in histologically graded invasive breast tumours using dynamic contrast-enhanced MRI. Br J Radiol 81, 120-128.
45. Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, and Dirnagl U (2007). Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 38, 2526-2530.
46. Favilla CG, Mullen MT, Ali M, Higgins P, and Kasner SE (2011). Sulfonylurea use before stroke does not influence outcome. Stroke 42, 710-715.